Table 1. Data to be collected for the United Kingdom national audit.

OCA: obeticholic acid; HCC: hepatocellular carcinoma; GOV: gastroesophageal varices; FRAX: Fracture Risk Assessment Tool; DEXA: dual-energy x-ray absorptiometry; BDM: bone mineral density; SLT: second-line therapy; UDCA: ursodeoxycholic acid

Treatment center

Patient age, sex, and weight

Results of contemporaneous laboratory investigations, including liver biochemistry, renal biochemistry, full blood count and blood clotting

Use of UDCA and dose, or documented reason for non-use of UDCA, where applicable

Record of response to UDCA

Record of risk stratification

Referral of UDCA non-responders for SLT, where applicable, or documented reason for non-referral of UDCA non-responder for SLT, where applicable

Use of OCA and dose, where applicable

Use of fibrates and dose, where applicable

Record of assessment for pruritus and fatigue

Use of specific anti-pruritic treatment (e.g. cholestyramine or rifampicin), where applicable

Record of BMD assessment (FRAX score or DEXA scan) within the last five years, and actions taken, if applicable

Record of HCC surveillance, where applicable

Record of GOV screening, where applicable

Record liver biopsy, where applicable

Record of referral to a liver transplant center, where applicable